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Summary 
Cyclooxygenases 1 and 2 (COX-1 and COX-2) are key 
enzymes in prostaglandin biosynthesis and the target 
enzymes for the widely used nonsteroidal anti-inflam- 
matory drugs. To study the physiological roles of the 
individual isoforms, we have disrupted the mouse 
Ptgsl gene encoding COX-1. Homozygous Ptgsl mu- 
tant mice survive well, have no gastric pathology, and 
show less indomethacin-induced gastric ulceration 
than wild-type mice, even though their gastric prosta- 
glandin EP levels are about 1% of wild type. The homo- 
zygous mutant mice have reduced platelet aggrega- 
tion and a decreased inflammatory response to 
arachidonic acid, but not to tetradecanoyl phorbol ace- 
tate. Pfgsl homozygous mutant females mated to ho- 
mozygous mutant males produce few live offspring. 
COX-l-deficient mice provide a useful model to distin- 
guish the physiological roles of COX-1 and COX-2. 
Introduction 
The cyclooxygenase isoforms, COX-1 and COX-2, cata- 
lyze the key step in the synthesis of prostaglandins. While 
COX-1 and COX-2 catalyze the same reaction, the conver- 
sion of arachidonic acid (AA) to prostaglandin Hn (PGH,), 
the isoforms appear to have different biological roles. 
COX-1 and COX-2 are also the target enzymes for the 
most widely used drugs in human medicine, nonsteroidal 
anti-inflammatorydrugs(NSAIDs). Thus, there isconsider- 
able interest in understanding the physiological roles of 
COX-1 and COX-2 and in developing drugs that differen- 
tially inhibit them. 
The COX isoforms are encoded by genes located on 
different chromosomes (Wen et al., 1993). The gene en- 
coding COX-1 (Pfgsl in the mouse) spans about 22 kb 
(Yokoyama and Tanabe, 1989; Kraemer et al., 1992), from 
which a message of 2.8 kb is derived (Dewitt and Smith, 
1988; Merlie et al., 1988; Yokoyama et al., 1988). The 
gene encoding COX-2 (Ptgs2 in the mouse) is about 8 kb 
(Xie et al., 1991; Kujubu et al., 1991; O’Banion et al., 1991) 
and produces a message of about 4.1 kb (Xie et al., 1991; 
Kujubu et al., 1991; O’Banion et al., 1991; Kujubu and 
Herschman, 1992; DuBois et al., 1994b). The COX-1 and 
COX-2 proteins from the same species are about 60% 
identical with the catalytic regions being conserved. 
The genes encoding COX-1 and COX-2 differ in their 
regulation at the transcriptional level, and recent data rein- 
force the likelihood that the isoforms mediate different 
biological functions (Morita et al., 1995; Murakami et al., 
1994). COX-1 appears to be constitutively synthesized in 
many tissues (Simmons et al., 1991; O’Neill and Ford- 
Hutchinson, 1993; Seibert et al., 1994) although its level 
of expression can vary with the state of differentiation or 
following cytokine or tumor promoter stimulation (Smith 
et al., 1993, 1994; Samet et al., 1995; Murakami et al., 
1995). COX-1 is thought to carry out primarily”housekeep- 
ing” functions such as cytoprotection of the gastric mu- 
cosa, regulation of renal blood flow, and platelet aggrega- 
tion (Dewitt and Smith, 1988, 1990; Merlie et al., 1988; 
Funk et al., 1991). In contrast, COX-2 message and pro- 
tein are normally undetectable in most tissues; however, 
COX-2 expression in certain cell types can be rapidly in- 
duced by proinflammatory or mitogenic agents, including 
cytokines, endotoxins, tumor promoters, and mitogens 
(Xie et al., 1991; O’Banion et al., 1992; Hla and Neilson, 
1992; Fletcher et al., 1992; DuBois et al., 1994a; Smith 
et al., 1994). Because of this rapid induction, the gene 
encoding COX-2 has been termed an immediate-early re- 
sponse or primary response gene (Simmons et al., 1989; 
Maier et al., 1990; Fletcher et al., 1992; Ryseck et al., 
1992). COX-2 message and protein have been shown to 
be up-regulated in human colon cancers (Eberhart et al., 
1994; Kargman et al., 1995) and in mouse skin papillomas 
and carcinomas (Muller-Decker et al., 1995). 
The COX isoforms are the primary target enzymes for 
NSAIDs, which act by inhibiting the activity of the enzymes 
(Vane, 1971; Smith and Willis, 1971; Smith et al., 1990; 
Xie et al., 1992; Seibert et al., 1994; Masferrer et al., 1994; 
Mitchell et al., 1994; Seibert and Masferrer, 1994). Aspirin, 
the most common and best-studied NSAID, was originally 
shown to inhibit prostaglandin synthesis by Vane (1971). 
NSAlDs in common use today include aspirin, ibuprofen, 
and indomethacin, and all inhibit the COX enzymes. In 
addition to the use of NSAlDs as analgesics and for alle- 
viation of acute and chronic inflammatory diseases such 
as arthritis (Levi and Shaw Smith, 1994; Simon, 1994) 
NSAlDs (in particular, aspirin) have proven effective for 
decreasing the frequency of heart attacks and strokes 
(Vane and Botting, 1992) and in reducing the incidence 
of colon cancer (Thun et al., 1991, 1993; Marnett, 1992). 
Some NSAlDs also inhibit chemically induced colon can- 
cer in rodents (Rao et al., 1995, and references therein). 
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From the combined evidence of NSAID effects on rodent 
and human colon cancers, it has been suggested that 
randomized prevention trials with humans be initiated 
(Heath et al., 1994). However, while NSAlDs have many 
beneficial effects, they can also cause adverse side ef- 
fects, the most common of which are gastrointestinal ul- 
ceration and nephrotoxicity (Clive and Stoff, 1984; Black, 
1986; Brooks and Day, 1991; Price and Fletcher, 1990; 
Simon, 1994). 
Since the discovery of COX-2, the identification of drugs 
that selectively inhibit this isoform has become the focus 
of NSAID development (Xie et al., 1992; Meade et al., 
1993; Seibert and Masferrer, 1994; Mitchell et al., 1994; 
Masferrer et al., 1994). The rationale for this is that COX-1 
is not elevated during inflammation and that, as a neces- 
sary housekeeping gene, its inhibition by NSAlDs may be 
the cause of their adverse side effects. In contrast, COX-2 
is normally nondetectable in most tissues, but is rapidly 
elevated during inflammation (Masferrer et al., 1994; Crof- 
ford et al., 1994; Vane et al., 1994; Mitchell et al., 1994; 
Seibert et al., 1994; Vane, 1994; Simmons et al., 1991), 
and its inhibition by NSAlDs is thought responsible for 
their therapeutic effects. 
The relative biological contributions of the COX-1 and 
COX-2 isoforms in the maintenance of normal physiologi- 
cal functions and in diseased states is not, however, en- 
tirely clear. Most of the current knowledge has come from 
studies of NSAID inhibition, COX-2 induction, or both. As 
an alternative approach to understand the roles of these 
enzymes better, we have used gene targeting to generate 
a mouse strain that is unable to synthesize COX-1. The 
development of COX-Bdeficient mice is reported by Mor- 
ham et al. (1995 [this issue of Ce//)). With these mice, we 
hope to learn more about the roles of the two isoforms in 
normal physiology and in various inflammatory disorders 
and to understand better the etiology of the therapeutic 
effects and deleterious side effects of NSAlDs. In the pres- 
ent study, we report the generation of mice lacking COX-1 
and some of their phenotypic characteristics. 
Results 
Cloning of the 3’ Region of the Ptgsl Gene 
The 3’ region of the mouse Pfgsl gene was cloned using 
a 357 bp probe synthesized from strain 129 mouse embry- 
onic stem (ES) cell DNA. The probe was made by polymer- 
ase chain reaction (PCR) with primers for the 5’ end of 
exon 11, the sequences of which were based on the hu- 
man COX-7 gene structure (Yokoyama and Tanabe, 1989) 
and the mouse cDNA sequence (Dewitt et al., 1990). This 
probe detected only a single band on Southern blots of 
mouse ES cell DNA digested with Xbal, Hindlll, Bglll, 
BamHI, or Sacl, indicating that it was specific for a single 
gene. The 15 kb fragment cloned wassubsequentlyshown 
to be from Pfgsl, and not the isoform PtgsP, by the follow- 
ing. First, three different primer pairs specific for se- 
quences in exon 11 of Ptgsl were used for PCR, and the 
predicted product sizes were obtained. Second, about 100 
bp of DNA 3’ of the Clal site in exon 11 (Figure 1A) was 
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Figure 1. Targeted Disruption of the Mouse Ptgsl Gene 
(A) The 3’ region of the Ptgsl gene. Closed boxes represent exons, 
and bars below represent the probes. Restriction sites: Bg, Bglll; B, 
BarnHI; C, Clal; H, Hindlll; X, Xbal; Xh, Xhol. 
(B) Targeting construct. Phosphoglycerolkinase-promoted neomycin 
and herpes simplex thymidine kinase genes are represented by Neo 
and Tk, respectively. Wavy lines represent plasmid (not to scale). N 
shows the linearizing Not1 restriction site. 
(C) Targeted Ptgsl locus. Diagnostic PCR primers are indicated by 
arrows. 
(D) Southern blot of Hindlll-digested targeted allele (2.8 kb) and wild- 
type allele (5.2 kb) mouse tail DNA. Wild type (+I+), heterozygotes 
(+I-), and homozygote mutants (-I-) are shown. 
sequenced from the fragment and shown to match the 
published sequence of Ptgsl (Dewitt and Smith, 1990). 
Third, PCR with primers specific for the 5’ and 3’ ends of 
Ptgsl exon 10 produced the correct sized product from 
the cloned fragment. Fourth, the 2.4 kb PCR fragment 
used to diagnose targeted clones (Figure 1 C) was digested 
by Bglll into fragments of the predicted sizes. 
Vector Construction and Targeting 
The targeting strategy for disruption of the Ptgsl gene is 
shown in Figure 1. Since aspirin inactivates COX-1 by 
acetylating Ser-530 (Humes et al., 1981; Roth et al., 1983; 
Dewitt et al., 1990), we disrupted the gene prior to the 
codon for this amino acid in exon 11. The targeting vector 
was designed to replace about 1 kb of intron 10, together 
with the splice junction and first 44 bp of exon 11, with 
the neomycin resistance (Neo) gene (Figure 1 B). If a pro- 
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tein were made from the resulting disrupted gene, it would 
lack the carboxy-terminal 120 amino acids, including Ser- 
530. Alternate splicing to eliminate the Neo gene would 
result in the elimination of 14 amino acids and loss of 
proper reading frame. 
The plasmid was linearized with Notl and electroporated 
intostrain 129-derived E14TG2a EScells. Following elec- 
troporation, G418 and ganciclovir selection was started 
(Mansour et al., 1988), and 6 of 96 doubly resistant colo- 
nies isolated were positive for the expected 2.4 kb PCR 
product indicated in Figure 1C. Using the exon 11 probe 
indicated in Figure lA, we confirmed targeting in these 
PC!+positive clones by detection on Southern blots of the 
expected 2.8 kb Hindlll fragment. The same 2.8 kb band 
was also detected with a 510 bp BamHI-Hindlll fragment 
that hybridizes to a genomic region 3’to the targeting con- 
struct (Figure 1 A). 
Production of Animals 
Cells from two of the targeted clones were injected into 
C57BL16J (B6) blastocysts, resulting in the birth of four 
male chimeras. One chimera produced heterozygous Fl 
129/B6 offspring after mating to B6 females. From the 
first seven F2 litters obtained by mating Fl heterozygous 
siblings, 14 wild-type, 31 heterozygous, and 16 homozy- 
gous mutant weanling pups were obtained, in agreement 
with Mendelian expectations (p > 0.9). Southern blots of 
Hindlll-digested tail DNA from wild-type F2, heterozygous 
F2, and homozygous mutant F2 mice are shown in Fig- 
ure 1D. 
General Health of the COX-l-Deficient Mice 
The COX-l-deficient mice develop normally and appear 
healthy. Necropsy and microscopic examination of se- 
lected tissues (liver, spleen, kidney, gastrointestinal tract, 
reproductive tract, heart, and lungs) from three homozy- 
gous mutant males and three homozygous mutant fe- 
males, aged 2-5 months, revealed no significant pathol- 
ogy. However, in three of six kidneys examined from 
homozygous mutant mice, a minimal change was present, 
characterized by one or two small foci per section of baso- 
philic, immature tubules. The size and frequency of these 
lesions did not change with age. All six wild-type age- 
matched controls did not show these foci. There were no 
consistent or remarkable findings in other tissues exam- 
ined, including the glandular and nonglandular stomach. 
Northern Blot Analysis of the COX-1 Message 
The effect of Ptgsl gene disruption on COX-7 mRNA was 
analyzed by determining the level of message in the colons 
and kidneys of wild-type, heterozygous, and homozygous 
mutant F2 mice using the 357 bp probe described above. 
Figure 2A shows that the level of full-length (2.8 kb) mes- 
sage is reduced to approximately half normal in the hetero- 
zygous mice. No 2.8 kb message is detected in the homo- 
zygous mutant mice. Similar results (data not shown) were 
obtained when the 1.7 kb fragment of mouse cDNA (Ox- 
ford Biomedical) was used as the probe. When the blots 
were rehybridized to a probe specific for the Neo gene, 
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Figure 2. Northern and Western Blot Analyses 
(A) Northern blot of total RNA from colon and kidney of wild-type 
(+I+), heterozygous (+I-), and homozygous mutant (-I-) mice. The 
blot was probed with a 357 bp PCR fragment from the COX-7 cDNA. 
(8) Western blot of microsomal protein from kidney, stomach, and 
colon of wild-type (+/+) and homozygous mutant (-/-) mice. The 
COX-1 standard is in the left lane. The protein was detected with a 
polyclonal antibody to COX-1. 
(C)Western blot of total protein from control and LPS-stimulated perito- 
neal macrophages from wild-type (+/+) and homozygous mutant 
(-I-) mice. (Top) COX-1 levels in control and LPS-stimulated perito- 
neal macrophages from wild-type and homozygous mutant mice: a 
COX-1 standard is on the left; the protein was detected with an antibody 
to COX-1. (Bottom) COX-2 levels in control and LPS-stimulated perito- 
neal macrophages from wild-type and homozygous mutant mice; a 
COX-2 standard is on the left; the protein was detected with a poly- 
clonal antibody to COX-2. 
a band at 1.1 kb was detected (data not shown) in the 
heterozygous and homozygous mutant RNA samples; as 
expected, the band was more intense in the homozygous 
mutant sample. The Neo probe did not hybridize with any 
band detected by the COX-1 probes. 
Western Blot Analysis of the COX-1 Protein 
A polyclonal antibody against residues 274-289 of COX-1 
(Morita et al., 1995) was used to determine the level of 
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COX-1 protein or any truncated product from the disrupted 
gene that includes these residues. Amino acids 274-289 
would still be present in a truncated protein if it were made, 
as the codons for these amino acids are 5’ to the site of 
gene disruption. Western blot analysis (Figure 2B) shows 
that the normal 70 kDa COX-1 protein is readily detectable 
in kidney, stomach, and colon microsomes of wild-type 
F2 Ptgsl mice. Neither normal-sized COX-1 protein nor 
any smaller fragment is detected in the same tissues from 
the homozygous mutant mice. Figure 2C (upper panel) 
demonstrates that COX-1 protein levels are not signifi- 
cantly affected by lipopolysaccharide (LPS) in macro- 
phages from wild-type mice and, as expected, are not de- 
tectable in the homozygous mutant mice. The bottom 
panel of Figure 2C shows that LPS induces the COX-2 
protein about equally in peritoneal macrophages from 
COX-1 wild-type and homozygous mutant mice. COX-2 
message and PGEz production are also induced about 
equally in the macrophages from wild-type and homozy- 
gous mutant mice (data not shown). These results indicate 
that disruption of Ptgsl prevents constitutive synthesis of 
COX-1 but does not alter PfgsP inducibility in macro- 
phages. 
PGE2 Production in Peritoneal Macrophages 
To determine the effect of Ptgsl gene disruption on prosta- 
glandin biosynthesis, we isolated and analyzed peritoneal 
macrophages for their basal (not LPS-stimulated) level of 
PGE2 production with exogenous AA as the substrate. The 
data in Figure 3 show that basal PGEp production is re- 
duced about 70% in heterozygous mice and is reduced 
more than 99% in homozygous mutant mice. The basal 
levels of PGE, production in the wild-type and heterozy- 
gous mice were not altered by a 6 hr incubation in medium 
containing dexamethasone, indicating that PGE, produc- 
tion is due to COX-1 and not to COX-2, the production of 
which is inhibited by dexamethasone. These data show 
that basal PGE, production is virtually absent in macro- 
phages from the Ptgsl disrupted mice and that COX-2 
contributes little to basal levels of PGE2 from exogenous 
AA in unstimulated macrophages. 
Gastric Ulceration 
The COX-1 homozygous mutant mice from F2 and subse- 
quent generations did not have gross or microscopic gas- 
tric lesions; therefore, the absence of COX-1 alone is not 
sufficient to cause lesions, Because COX-1 is a target for 
NSAlDs (Xie et al., 1992; Seibert et al., 1994; Masferrer 
et al., 1994; Mitchell et al., 1994; Seibert and Masferrer, 
1994) and because NSAID inhibition of COX-1 has been 
thought causal in the induction of gastrointestinal lesions, 
we investigated the possibility that COX-l-deficient mice 
have altered sensitivity to indomethacin, an NSAID known 
to induce stomach ulceration in mice (Yokoyama et al., 
1985; Rainsford, 1987; Ettarh and Carr, 1993). First, a 
dose response was determined by administering indo- 
methacin to heterozygous F-2 mice by gavage at doses 
ranging from 10 to 80 mglkg (data not shown). Doses of 
10 and 20 mglkg were found to be in the lower, but still 
+I+ +I- -I- 
Figure 3. Production of PGE, by Peritoneal Macrophages 
PGE2 levels were determined by radioimmunoassay, and the data are 
expressed as picograms of PGE, per IO3 cells. Data are for macro- 
phages from five mice for each genotype (wild type, heterozygous, 
and homozygous mutant). Data are presented as the mean f SEM. 
detectable, response range. The data in Figure 4 show 
that F2 and F3 wild-type and homozygous mutant mice 
treated with 20 mglkg have about an equal number of 
ulcers, although the percent of surface area ulcerated is 
somewhat reduced in the homozygous mutant mice (p < 
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Figure 4. Induction of Stomach Ulceration by lndomethacin in Wild- 
Type and Homozygous Mutant Mice 
(A) Data are expressed as the number of lesions of glandular stomach 
ulcers per animal at 10 and 20 mglkg indomethacin. (B) Data are 
expressed as the percent ulcerated areaofthe total glandular stomach 
surface areaat 10 and 20 mglkg indomethacin. For (A) and(B), 10 mgl 
kg wild type (n = 9), homozygous mutant (n = 6); 20 mglkg wild-type 
(n = 7), homozygous mutant (n = 8). Data are presented as the mean 
+ SEM. 
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Figure 5. Induction of Ear Inflammation by AA and TPA 
Data are expressed as the percent increase over pretreatment ear 
thickness, ForAAandTPAtreatmentqfiveandfourmice, respectively, 
of the F2 genotype indicated (wild type, heterozygous, homozygous 
mutant) were used. The mean control ear thickness was 0.22 f 0.02 
mm. Data are presented as the mean f SEM. 
0.36). At the 10 mg/kg dose, the homozygous mutant mice 
had statistically fewer lesions (p < 0.04), and a lower per- 
cent of stomach surface area was ulcerated (p < 0.06) 
than in the wild-type mice. 
A possible means whereby gastric cytoprotection might 
be achieved in the COX-1 homozygous mutant mice is 
via a compensatory production of prostaglandins by the 
COX-2 isoform. To investigate this possibility, we deter- 
mined PGE2 levels in the glandular stomachs of COX-1 
homozygous mutant mice and compared these levels with 
those in wild-type mice, untreated or after gavage with 40 
mglkg of indomethacin. Untreated wild-type levels were 
113,430 + 5,430 pg per milligram of tissue (n = 2); treated 
wild-type were 353 + 126 pg per milligram of tissue 
(n = 2); homozygous mutant levels were 713 r 265 pg 
per milligram of tissue (n = 2). Thus, it appears that COX-2 
is contributing little to PGE2 production in the stomach of 
COX-1 homozygous mutant mice. 
Ear Inflammation 
A standard ear swelling assay (Gad et al., 1986; Opas et 
al., 1985) was used to determine whether mice with the 
Ptgsl gene disruption had an altered inflammatory re- 
sponse to chemical challenge. The mice used in these 
studies were littermates from the F2 generation. Figure 5 
shows that when AA was administered topically, the homo- 
zygous mutant mice had a significantly reduced (p< 0.002) 
inflammatory response (about 30% normal). The hetero- 
zygous mice also had a decreased response, although it 
did not reach statistical significance (p < 0.26). In contrast, 
inflammation in response to the potent tumor promoter 
tetradecanoyl phorbol acetate (TPA) did not differ in the 
wild-type and homozygous mutant mice. By 6 hr after treat- 
ment with AA, ear thickness had returned to normal, while 
TPA-treated ears remained inflamed for at least 18 hr after 
treatment. 
In gene targeting experiments in which breeding is not 
confined to a single inbred strain of mice, the cosegrega- 
tion of strain differences in genes linked to the target locus 
must be considered (Smithies and Maeda, 1995). In the 
present instance, this complication is effectively elimi- 
nated by the observations of Morham et al. (1995); their 
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Figure 6. AA-Induced Aggregation of Platelets from Wild-Type F2 and 
Homozygous F2 Mutant Mice 
(A) Solvent control with platelets from wild-type mice. (B) Platelets plus 
AAfrom homozygous mutant mice. (C)Platelets plus AAfrom wild-type 
mice. 
wild-type F2 PtgsP animals, in which the wild-type Ptgsl 
locus and linked genes from the B6 and 129 strains can 
occur in all combinations, did not differ significantly in re- 
sponse to AA from our F2 wild-type animals carrying only 
the Ptgsl B6/B6 combination. 
Platelet Aggregation 
COX-1 is considered the key enzyme for generating pros- 
taglandins involved in platelet aggregation (Funk et al., 
1991). We therefore investigated the ability of platelets 
from wild-type and homozygous mutant mice to aggregate 
in vitro. The curves in Figure 6 show that platelets from 
homozygous mutant mice aggregate more slowly and to 
a lesser extent in response to AA than do platelets from 
wild-type mice. 
Reproductive Capability of Homozygous 
Mutant Mice 
Table 1 lists the frequency of live births and the litter sizes 
resulting from different heterozygous and homozygous 
matings. When homozygous mutant females are mated 
with homozygous mutant males, almost all of the pups 
are found dead, even though the litter sizes are normal. 
The cause of pup death has not been determined. In con- 
Table 1. Effect of Parental Genotype on Litter Size and Pup Survival 
Pairing 
Postnatal Survivors Averaae 
Male Female per Total Births” Litter Size” 
Homozygous x homozygousb 4 of 39 7.8 f 1.2 
Heterozygous x homozygous 20 of 26 6.5 f 1.0 
Homozygous x heterozygous 27 of 31 7.8 k 0.5 
a Data are based on four litters for the heterozygous x homozygous 
and five litters for the homozygous x homozygous pairs mated. 
’ Four different homozygous females, one of which produced two 
litters. 
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trast, when homozygous mutant females are mated with 
heterozygous males, the number of surviving pups and 
the litter sizes are close to normal, with the number of 
pups having the heterozygous and homozygous mutant 
genotypes being essentially equal. The breeding of homo- 
zygous mutant males to heterozygous females likewise 
results in normal pup survival and litter size. These data 
indicate that both homozygous mutant males and homozy- 
gous mutant females are fertile, but that pup survival is 
decreased when homozygous mutant mice are mated to 
each other; in this situation, neither the female nor the 
pups have functional COX-1. 
Discussion 
In the present study, we have used homologous recombi- 
nation to disrupt the mouse Ptgsl gene that encodes 
COX-1. The major findings are that COX-1 -deficient mice 
are generally healthy, do not have spontaneous stomach 
ulcers, and show less gastric ulceration than wild-type 
mice after gavage with indomethacin. The homozygous 
mutant mice also have a reduced inflammatory response 
to AA, and homozygous mutant x homozygous mutant 
matings result in reduced pup survival. 
Because the stomach and kidney are two tissues where 
COX activity had been thought essential for proper func- 
tion (Robert, 1975, 1979; Clive and Stoff, 1984; Black, 
1986; Brooks and Day, 1991; Price and Fletcher, 1990; 
Simon, 1994), the lack of pathology in these tissues of 
COX-1 -deficient mice was surprising. Furthermore, based 
on the hypotheses that COX-1 is a housekeeping enzyme 
and that NSAID inhibition of COX-1 is responsible forstom- 
ach ulceration, we had expected that COX-1 deficiency 
might lead to spontaneous stomach ulceration or bleeding 
in the homozygous mutant mouse. But the gastrointestinal 
tissues of the homozygous mutants were not distinguish- 
able from wild type. Thus, absence of COX-1 is not suffi- 
cient to cause stomach ulceration in mice. Furthermore, 
measurement of PGE2 in the glandular stomach of COX-1 
homozygous mutant mice indicates that PGE2 levels per 
milligram of tissue are less than 1% of the levels observed 
in wild-type mice. This reduction is consistent with that 
observed in peritoneal macrophages from homozygous 
mutant mice (Figure 3) and is approximately equal to the 
levels-observed in the stomachs of wild-type mice treated 
with 40 mglkg indomethacin. The low level of PGEz in 
the glandular stomach of the homozygous mutant mice 
coupled with the finding that COX-2 is undetectable by 
Western blot analysis (data not shown) suggests that com- 
pensation by COX-2 is not a significant factor in this tissue 
in COX-1 homozygous mutant mice. 
Because of the absence of spontaneous gastric ulcer- 
ation in the COX-l-deficient mice, we determined whether 
they have an altered sensitivity to NSAID-induced gastric 
ulceration. For this we chose indomethacin, which is widely 
used in NSAID studies of gastric ulceration and is known 
to induce ulceration in the mouse stomach (Yokoyama et 
al,, 1985; Rainsford, 1987; Ettarh and Carr, 1993). Our 
experiments confirm that wild-type mice are sensitive to 
stomach ulceration by indomethacin gavaged at either 10 
or 20 mglkg, doses commonly used to cause ulceration 
in rats (Futaki et al., 1993; Rainsford, 1993; Beck et al., 
1990). Surprisingly, we found that the homozygous Pfgsl 
homozygous mutants are less sensitive to indomethacin- 
induced stomach ulceration than are the wild-type mice: 
the absence of COX-1 decreases rather than increases 
the incidence of ulceration after indomethacin treatment. 
Thus, these observations suggest that indomethacin- 
induced gastric ulceration may be due to mechanisms 
other than (or in addition to) COX-1 inhibition. Alterna- 
tively, in the development of gastric ulcers, lack of COX-1 
activity due to gene disruption may not be equivalent to 
the inhibition of COX-1 activity by indomethacin. As de- 
scribed by Morham et al. (1995), mice deficient in COX-2 
also show no spontaneous stomach ulcers or overt intesti- 
nal lesions. These data emphasize that the relationship 
between inhibition of COX activity and ulceration is 
complex, and they illustrate that the COX-l- and COX-2- 
deficient mice provide novel ways of studying isoform- 
specific NSAlDs and for identifying mechanisms in addi- 
tion to COX’inhibition that may be involved in the ulcerative 
process. 
The kidneys of the COX-l-deficient mice showed only 
minimal abnormalities even at 5 months of age. Therefore, 
absence of COX-1 in the kidney is not deleterious under 
normal physiological conditions. 
Prostaglandins have key functions in various stages of 
the reproductive process, ranging from ovulation and sper- 
matogenesis to parturition (Thorburn, 1991,1992; Zahrad- 
nik et al., 1992). Which COX isoform is involved in each 
of these stages is not known, except for ovulation, when 
it appears that COX-2 is the important form (Sirois et al., 
1992). Our studies show that neither male nor famale fertil- 
ity appears to be affected by lack of COX-1 (Table l), but 
they clearly show that complete lack of COX-1, such as 
occurs in homozygous mutant x homozygous mutant 
matings, severely impedes survival of pups perinatally. 
Because prostaglandins are known to be involved in the 
initiation of labor (Kelly, 1994), it may be the onset of labor 
that is impaired. However, the normal litter size and pup 
survival seen when heterozygous males are mated with 
homozygous mutant females show that absence of COX-1 
synthesis in the mother can be overcome by the presence 
of COX-1 in as few as 50% of the pups or in their placental 
material. From these matings, heterozygous and homozy- 
gous mutant pups are born in about equal numbers. The 
mating of homozygous mutant males with heterozygous 
females likewise results in normal litter sizes and pup sur- 
vival. The most likely explanation for these observations 
is that prostaglandins from the COX-1 pathway in either 
the maternal or fetal tissues are essential for normal partu- 
rition. Further studies are needed to elucidate the roles 
of the COX isoforms in pregnancy and parturition, and the 
COX-deficient mice should provide useful models for such 
studies. 
The decrease in AA-induced platelet aggregation seen 
in our COX-1 -deficient mice accords well with existing data 
that platelets contain the constitutively produced isoform 
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COX-1 (Funk et al., 1991). Since platelets lack nuclei, this 
deficiency cannot be overcome by any compensatory in- 
duction of Pfgs2 transcription followed by COX-2 syn- 
thesis. 
The COX-l-deficient mice clearly have a reduction in 
their responses to AA, although their responses to TPA 
do not differ from wild type. However, the COX-P-deficient 
animals are as sensitive to inflammation caused by both 
AA and TPA as are wild-type mice. A possible reason for 
the differences between AA and TPA effects in the COX-l- 
deficient mice is that AA in wild-type mice (and COX-2- 
deficient mice) can be immediately metabolized by the 
constitutive COX-1 enzyme to PGH, and subsequently 
to PGE,, which contributes to edema and inflammation. 
Since this cannot occur in the COX-1 homozygous mutant 
mice, less inflammation occurs. TPA, on the other hand, 
does not interact directly with COX-1 but is known to in- 
duce the synthesis of other enzymes, including COX-2 in 
vitro (Kujubu et al., 1991; DuBois et al., 1994a) and in vivo 
(Muller-Decker et al., 1995). The finding that TPA-induced 
inflammation is equal in COX-2 homozygous mutant mice 
and wild-type mice indicates that COX-2 is not essential 
for this type of inflammation to occur in the skin of these 
mice. Thus, it appears that COX-1 can contribute to inflam- 
mation. More detailed studies of the responses of the 
COX-l- or COX-2-deficient mice will be needed to indicate 
the relative roles of the two isoforms following different 
types of inflammatory stimuli. 
The major conclusions from the present study are that 
lack of COX-1 does not cause spontaneous gastric ulcer- 
ation and decreases indomethacin-induced ulceration, 
that it decreases inflammatory responses to AA, that it 
decreases platelet aggregation, but that it has no other 
overt systemic effects except those associated with partu- 
rition. Lackof COX-2, as reported by Morham et al. (1995), 
also does not cause spontaneous stomach ulceration, but, 
in contrast with lack of COX-1, it has no effect on inflamma- 
tory responses to AA, causes severe kidney disease, and 
leads to spontaneous peritonitis in some animals. 
Experimental Procedures 
Targeting Vector Construction 
A Charon 35 genomic library containing DNA from E14TG2a mouse 
ES cells (Hooper et al., 1987) was screened with a 357 bp probe (see 
below) for the 5’ end of exon 11 of the mouse Ptgsl gene. A clone 
containing approximately 15 kb of the 3’ end of the Ptgsl gene was 
isolated, and overlapping 6 kb Xbal and Clal fragments (Figure 1A) 
were subcloned into Bluescript. A 4.3 kb Notl-Xhol fragment of the 
Xbal subclone was inserted into the pPNT vector (Tybulewicz et al., 
1991) 5’to the Neo gene, and a 2.3 kb BamHl fragment from the Clal 
subclone was inserted 3’ to the Neo gene to produce the targeting 
construct (Figure 1 B). 
Cell Culture and Targeting 
E14TG2a ES cells were cultured by conventional methods on feeder 
cells. The targeting vector was linearized with Notl and electroporated 
at 5 nM into about lOa trypsinized ES cells using a 1 s pulse at 300 
V and 200 uF. Positive/negative selection was performed with G418 
and ganciclovir (Mansour et al., 1988) with ganciclovir providing about 
a 1 O-fold enrichmentoverG418 alone. Ganciclovir-and G41 &resistant 
colonies were Isolated 8-9 days after electroporation and transferred 
individually to 24-well plates previously seeded with feeder cells, The 
cells were trypsinized 2 days later and reseeded into 6-well plates. 
After 2 days the cells were trypsinized, and about half were frozen at 
-80°C. DNA isolated from the remaining half was used for PCR and 
genomic Southern blot analysis. 
PCR and Southern Blot Analysis 
PCR was the initial screen for identifying targeted ES cells and mice 
carrying the disrupted COX-7 gene (Kim and Smithies, 1988). A primer 
specific for the Neo gene and a second primer specific for a genomic 
sequence 3’to sequences in the targeting construct (Figure 1C) pro- 
duced a single 2.4 kb band diagnostic of targeting. Genomic Southern 
blotswere produced by standard techniques and probed with a random 
primer 32P-labeled probe (Stratagene Prime-h II) made from the 357 
bp PCRfragment specificforthe5’region of exon Il. DNAwas isolated 
from mouse tails to determine genotype. 
Northern Blot Analysis 
Total RNA was isolated from tissues by homogenizing them in TRlzol 
(Life Technologies) or from cells by scraping directly into TRlzol as 
recommended by the supplier. Each sample (15 ug) was electropho- 
resed in a2.2 M formaldehyde-0.9% agarose gel. After capillary trans- 
fer, the blot was hybridized with a random primer 32P-labeled probe 
made from the exon 1 l-specific 357 bp PCR fragment or a 1.7 kb 
COX-1 cDNA fragment (Oxford Biomedical Research Corporation). 
Blots were stripped and probed for actin to ensure equal loading 
of RNA. 
Western Blot Analysis 
To prepare microsomes, we homogenized tissues in buffer(0.1 M Tris- 
HCI [pH 7.4],2 mM EDTA, 10 mglml leupeptin, 20 mg/ml aprotinin, 0.5 
mM phenylmethylsulfonyl fluoride) and then sonicated them at 30% 
power (Fisher Scientific, Model F50) three times for 15 s. The homoge- 
nates were centrifuged at 10,000 x g for 15 min at 4°C. The resulting 
supernatants were centrifuged at 100,000 x g for 1 hr at 4°C and 
the microsomal pellets were sheared in buffer (100 mM Tris [pH 6.81, 
8% SDS, 20% glycerol) with a 25-gauge needle. An aliquot was re- 
moved for protein determination (Bio-Rad DC) before boiling with bro- 
mophenol blue (0.05% [w/v]) and 2-mercaptoethanol (6% [v/v]). 
For immunoblot analysis, 40 frg of microsomal protein (kidney and 
stomach), 20 ug of microsomal protein (colon), or 10 ug of protein 
from cell lysate (macrophages) were separated by SDS-PAGE using 
the Mini-PROTEAN II electrophoretic apparatus (Bio-Rad). Proteins 
were transferred onto Hybond-ECL nitrocellulose (Amersham) using 
the Mini Trans-Blot electrophoretic transfer cell system (Bio-Rad). 
Membranes were blocked in 5% nonfat milk-Tris-buffered saline with 
0.1% Tween 20 (TEST) before incubating with a rabbit antibody to 
murine COX-1 provided by Dr. D. Dewitt (Morita et al., 1995) or to 
COX-2 (Cayman Chemical). Blots were incubated with anti-rabbit IgG 
horseradish peroxidase-linked secondary antibody (Boehringer Mann- 
heim) in TBST and 1% nonfat milk. Chemiluminescent detection was 
performed using reagents from Amersham, and bands werevisualized 
after exposure to Hyperfilm-ECL (Amersham). 
Indomethacin-Induced Stomach Ulceration 
lndomethacin wassuspended in 1% methyl cellulose at theconcentra- 
tion of 1 or 2 mg/ml and given at the stated doses by gavage. All animals 
were fasted 16-18 hr prior to Savage. Animals were euthanized using 
CO, 6 hr after treatment, and their stomaches were removed and 
opened along the lesser curvature. Stomach lesions were scored as 
described by Ghanayem et al. (1987). The number of lesions were 
counted, an enlarged image of the formalin-fixed glandular stomach 
and of each individual lesion was traced, and the area of each lesion 
was determined using a computer-assisted image analysis system. 
The total area of the stomach was traced and measured. The area of 
all lesions in each stomach was calculated and divided by the area 
of the glandular stomach to derive the percent of area with lesions. All 
samples were scored blind. No ulceration was shown by eight wild-type 
mice that received vehicle alone. 
Mouse Ear Inflammation Assay 
AA (2 mg per 10 ul) or TPA (1 ug per 10 ul) in acetone was applied 
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to the inside of the left ear and 10 ~1 of acetone was applied to the 
right ear as described by Opas et al. (1985). Ear swelling was deter- 
mined after 2 hr for AA or 6 hr for TPA by the method of Gad et al. 
(1986). 
Macrophage Isolation and PGEz Analysis 
Peritoneal macrophages were isolated and LPS stimulated by modifi- 
cation of the procedure of Watanabe et al. (1994). Thioglycolate- 
elicited macrophages were isolated by peritoneal lavage with 5 ml of 
cold RPM1 1840 medium. Macrophages were seeded at 1 x lo7 to 
2.5 x 10’ cells per 60 mm dish, depending on yield, and allowed to 
attach for 2 hr in a humidified incubator with 5% CO* in air. The plates 
were then washed with Hanks balanced salt solution to remove nonad- 
hering ceils, and medium containing 1% serum with or without LPS 
(10 pglml) was then added. Attached cell numbers were determined 
by counting with an eyepiece micrometer. After a 6 hr incubation, the 
medium was removed and replaced for30 min with medium containing 
10 KM AA. Subsequent analysis for PGE? in the medium was by a 
competitive radioimmunoassay (Amersham). 
Platelet Aggregation 
Platelet aggregation was carried out as described by Paigen et al. 
(1987) using AA to induce aggregation. For each assay, blood was 
pooled from two mice (about 1 ml in total volume) and centrifuged to 
prepare platelet-rich and then platelet-poor plasma. The assay was 
conducted with 300 ~1 of plasma at 3 x lOa platelets per milliliter, 
Aggregation was induced by adding 15 frl of Na-AA (22 mg/ml in 
NazC03 buffer). Turbidity was measured with a Lumi-Aggregometer. 
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